# SLC25A22

## Overview
SLC25A22 is a gene that encodes the mitochondrial carrier protein known as solute carrier family 25 member 22 (SLC25A22). This protein is a transmembrane transporter that plays a critical role in the mitochondrial uptake of glutamate, functioning as a glutamate/H+ symporter. It is predominantly expressed in the brain, particularly in astrocytes, where it is essential for maintaining glutamate homeostasis and supporting cellular energy metabolism (Lemattre2019Report; Goubert2017Inhibition). The proper function of SLC25A22 is crucial for neuronal activity and energy production, linking it to the mitochondrial respiratory chain and influencing NAD(P)H and ATP synthesis (Goubert2017Inhibition). Mutations in the SLC25A22 gene are associated with severe neurological disorders, including early infantile epileptic encephalopathy, highlighting its clinical significance (Palmieri2020Diseases).

## Structure
The SLC25A22 protein is a member of the mitochondrial carrier family, characterized by a tripartite structure with six transmembrane alpha-helices. These helices form a bundle around a central cavity, facilitating the transport of glutamate into the mitochondrial matrix (Palmieri2013The; Palmieri2004The). The protein's structure includes three tandemly repeated homologous domains, each approximately 100 amino acids long, with hydrophobic stretches that span the membrane as alpha-helices, separated by hydrophilic regions (Palmieri2004The). 

The SLC25A22 protein functions as a glutamate/H+ symporter, playing a crucial role in glutamate metabolism within mitochondria (Lemattre2019Report). It is highly expressed in the brain, particularly in astrocytes, where it regulates glutamate uptake (Goubert2017Inhibition). Mutations affecting the substrate translocation pore of SLC25A22 are associated with severe disease phenotypes, such as early infantile epileptic encephalopathy type 3 (Palmieri2020Diseases). 

The protein may undergo post-translational modifications, such as phosphorylation, which can influence its function and localization. Variants of SLC25A22 can arise from alternative splicing, potentially affecting its structural and functional properties.

## Function
The SLC25A22 gene encodes a mitochondrial glutamate carrier protein, known as GC1, which is crucial for transporting glutamate into the mitochondrial matrix. This transport is facilitated by a glutamate/H+ symporter mechanism, primarily active in astrocytes within the brain (Lemattre2019Report; Goubert2017Inhibition). Once inside the mitochondria, glutamate is converted by glutamate dehydrogenase into ammonium ions and 2-oxoglutarate. The ammonium ions participate in the urea cycle, while 2-oxoglutarate is involved in gluconeogenesis or oxidized in the TCA cycle for ATP production (Palmieri2020Diseases).

SLC25A22 is highly expressed in brain regions associated with motor coordination and is essential for maintaining extracellular glutamate levels, which is critical for normal neuronal function (Lemattre2019Report). The protein's activity supports cellular energy metabolism by contributing to NAD(P)H production and ATP synthesis, linking it to the mitochondrial respiratory chain (Goubert2017Inhibition). Proper function of SLC25A22 is vital for cellular energy homeostasis and neurotransmitter regulation, impacting brain function and development (Goubert2017Inhibition). Deficiency or dysfunction in this protein can lead to intracellular glutamate accumulation and associated neurological disorders (Goubert2017Inhibition).

## Clinical Significance
Mutations in the SLC25A22 gene are linked to several severe neurological disorders, primarily forms of early-onset epileptic encephalopathy. These include severe neonatal epileptic encephalopathy with suppression bursts (NEESB), early infantile epileptic encephalopathy type 3 (EIEE3), Ohtahara Syndrome (OS), Early Myoclonic Encephalopathy (EME), and Malignant Migrating Partial Seizures of Infancy (MMPSI) (Palmieri2020Diseases; Nicotera2021De; André2021The). These conditions are characterized by early-onset seizures, severe developmental delays, hypotonia, microcephaly, and suppression-burst patterns on EEGs (Palmieri2020Diseases; André2021The).

The severity of the disorders correlates with the specific mutations within the SLC25A22 gene, particularly those affecting the substrate translocation pore, which are associated with more severe phenotypes (Palmieri2020Diseases). For instance, a homozygous missense mutation (c.97A>G; p.Lys33Glu) has been reported to cause a complex phenotype with early-onset epileptic encephalopathy, hypotonia, and global developmental delay (Nicotera2021De). Dysfunction in SLC25A22 leads to impaired mitochondrial glutamate transport, resulting in dysregulated extracellular glutamate levels, which contribute to the neurological symptoms observed in affected individuals (Palmieri2020Diseases; Goubert2017Inhibition).

## Interactions
SLC25A22, a mitochondrial glutamate transporter, is involved in several interactions that influence cancer progression and immune responses. In KRAS-mutant colorectal cancer, SLC25A22 plays a role in glutamine metabolism, which is crucial for the secretion of the chemokine CXCL1. This process involves the activation of SRC kinase, which acts as an asparagine sensor, leading to the ETS2-mediated transcription of CXCL1. The interaction between asparagine and SRC kinase is significant, as asparagine stabilizes and activates SRC, which is dependent on SLC25A22 (Zhou2023Targeting).

SLC25A22 also interacts with the MAPK/ERK signaling pathway in gallbladder cancer. Its expression is linked to the activation of this pathway, promoting cancer cell proliferation and metastasis. The downregulation of SLC25A22 results in decreased levels of phosphorylated MEK and ERK, indicating its role in activating these proteins (Du2019SLC25A22).

These interactions highlight SLC25A22's involvement in critical signaling pathways that regulate immune cell recruitment and cancer cell behavior, making it a potential target for therapeutic interventions in certain cancers (Du2019SLC25A22; Zhou2023Targeting).


## References


[1. (Du2019SLC25A22) Pengcheng Du, Haibin Liang, Xiaowei Fu, Peng Wu, Chao Wang, Haimin Chen, Bingbing Zheng, Jun Zhang, Shuanghui Hu, Rengui Zeng, Bo Liang, and Lu Fang. Slc25a22 promotes proliferation and metastasis by activating mapk/erk pathway in gallbladder cancer. Cancer Cell International, February 2019. URL: http://dx.doi.org/10.1186/s12935-019-0746-9, doi:10.1186/s12935-019-0746-9. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-019-0746-9)

[2. (Palmieri2020Diseases) Ferdinando Palmieri, Pasquale Scarcia, and Magnus Monné. Diseases caused by mutations in mitochondrial carrier genes slc25: a review. Biomolecules, 10(4):655, April 2020. URL: http://dx.doi.org/10.3390/biom10040655, doi:10.3390/biom10040655. This article has 75 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom10040655)

[3. (Goubert2017Inhibition) Emmanuelle Goubert, Yanina Mircheva, Francesco M. Lasorsa, Christophe Melon, Emanuela Profilo, Julie Sutera, Hélène Becq, Ferdinando Palmieri, Luigi Palmieri, Laurent Aniksztejn, and Florence Molinari. Inhibition of the mitochondrial glutamate carrier slc25a22 in astrocytes leads to intracellular glutamate accumulation. Frontiers in Cellular Neuroscience, May 2017. URL: http://dx.doi.org/10.3389/fncel.2017.00149, doi:10.3389/fncel.2017.00149. This article has 41 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2017.00149)

[4. (Palmieri2013The) Ferdinando Palmieri. The mitochondrial transporter family slc25: identification, properties and physiopathology. Molecular Aspects of Medicine, 34(2–3):465–484, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.05.005, doi:10.1016/j.mam.2012.05.005. This article has 612 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.05.005)

[5. (Nicotera2021De) Antonio Gennaro Nicotera, Daniela Dicanio, Erica Pironti, Maria Bonsignore, Anna Cafeo, Stephanie Efthymiou, Patrizia Mondello, Vincenzo Salpietro, Henry Houlden, and Gabriella Di Rosa. De novo mutation in slc25a22 gene: expansion of the clinical and electroencephalographic phenotype. Journal of Neurogenetics, 35(2):67–73, April 2021. URL: http://dx.doi.org/10.1080/01677063.2021.1892094, doi:10.1080/01677063.2021.1892094. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/01677063.2021.1892094)

[6. (Palmieri2004The) Ferdinando Palmieri. The mitochondrial transporter family (slc25): physiological and pathological implications. Pfl�gers Archiv European Journal of Physiology, 447(5):689–709, February 2004. URL: http://dx.doi.org/10.1007/s00424-003-1099-7, doi:10.1007/s00424-003-1099-7. This article has 624 citations.](https://doi.org/10.1007/s00424-003-1099-7)

[7. (André2021The) M.-V. André, P. Cacciagli, A. Cano, L. Vaugier, M. Roussel, N. Girard, B. Chabrol, L. Villard, and M. Milh. The phenotype caused by recessive variations in slc25a22: report of a new case and literature review. Archives de Pédiatrie, 28(1):87–92, January 2021. URL: http://dx.doi.org/10.1016/j.arcped.2020.10.015, doi:10.1016/j.arcped.2020.10.015. This article has 1 citations.](https://doi.org/10.1016/j.arcped.2020.10.015)

[8. (Lemattre2019Report) Camille Lemattre, Marion Imbert-Bouteille, Vincent Gatinois, Paule Benit, Elodie Sanchez, Thomas Guignard, Frédéric Tran Mau-Them, Emmanuelle Haquet, François Rivier, Emilie Carme, Agathe Roubertie, Anne Boland, Doris Lechner, Vincent Meyer, Julien Thevenon, Yannis Duffourd, Jean-Baptiste Rivière, Jean-François Deleuze, Constance Wells, Florence Molinari, Pierre Rustin, Patricia Blanchet, and David Geneviève. Report on three additional patients and genotype–phenotype correlation in slc25a22-related disorders group. European Journal of Human Genetics, 27(11):1692–1700, July 2019. URL: http://dx.doi.org/10.1038/s41431-019-0433-2, doi:10.1038/s41431-019-0433-2. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41431-019-0433-2)

[9. (Zhou2023Targeting) Qiming Zhou, Yao Peng, Fenfen Ji, Huarong Chen, Wei Kang, Lam-Shing Chan, Hongyan Gou, Yufeng Lin, Pingmei Huang, Danyu Chen, Qinyao Wei, Hao Su, Cong Liang, Xiang Zhang, Jun Yu, and Chi Chun Wong. Targeting of slc25a22 boosts the immunotherapeutic response in kras-mutant colorectal cancer. Nature Communications, August 2023. URL: http://dx.doi.org/10.1038/s41467-023-39571-6, doi:10.1038/s41467-023-39571-6. This article has 13 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-39571-6)